Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy

Cancer Research

Volumn 67, Issue 16, 2007, Pages 7646-7653

  Li, Xiao Feng ^a   Carlin, Sean ^a   Urano, Muneyasu ^a   Russell, James ^a   Ling, C Clifton ^a   O'Donoghue, Joseph A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CARBOGEN; CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; HOE 33342; PIMONIDAZOLE;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES TUMOR; CELL HYPOXIA; CELL PROLIFERATION; COLORECTAL ADENOCARCINOMA; CONTROLLED STUDY; FEMALE; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; PERITONEUM TUMOR; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ASCITES; CARBON DIOXIDE; CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; OXYGEN; PERITONEAL NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 34548018979     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4353     Document Type: Article

References (39)

1. Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240-57.
2. Goethals L, Debucquoy A, Perneel C, et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 2006;65:246-54.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
4. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
5. 2 tension measurements. Cancer Res 1991;51:3316-22.
6. Teicher BA. Hypoxia and drug-resistance. Cancer Metastasis Rev 1994;13:139-68.
7. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance, and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307.
8. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:59-67.
9. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebocontrolled trial. Lancet Oncol 2005;6:757-64.
10. Zhao DW, Constantinescu A, Hahn EW, Mason RP. Tumor oxygen dynamics with respect to growth and respiratory challenge: investigation of the Dunning prostate R3327-HI tumor. Radiat Res 2001;156:510-20.
11. De Jaeger K, Merlo FM, Kavanagh MC, Fyles AW, Hedley D, Hill RP. Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. Int J Radiat Oncol Biol Phys 1998;42:717-21.
12. Milross CG, Tucker SL, Mason KA, Hunter NR, Milas L. The effect of tumor size on necrosis and polarographically measured pO(2). Acta Oncol 1997;36:183-9.
13. Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999;151:580-9.
14. Kaanders J, Wijffels K, Marres HAM, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74.
15. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998;58:3765-8.
16. Driessen A, Landuyt W, Pastorekova S, et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006;243:334-40.
17. Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUTI and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 2003;89:1290-7.
18. Potter CPS, Harris AL. Diagnostic, prognostic, and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2-7.
19. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-403.
20. Beasley NJP, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61:5262-7.
21. Chrastina A, Zavada J, Parkkila S, et al. Biodistribution and pharmacokinetics of I-125-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003;105:873-81.
22. Vordermark D, Kaffer A, Riedl S, Katzer A, Flentje M. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 2005;61:1197-207.
23. Gross MW, Karbach U, Groebe K, Franko AJ, Muellerklieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen-tension and labeling density in multicellular spheroids. Int J Cancer 1995;61:567-73.
24. Schneider RF, Engelhardt EL, Stobbe CC, Fenning MC, Chapman JD. The synthesis and radiolabeling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class. J Labeled Compounds Radiopharm 1997;39:541-57.
25. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O-2 tension. Am J Physiol Cell Physiol 1996;40:C1172-80.
26. Sorensen BS, Hao J, Overgaard J, et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 2005;76:187-93.
27. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011-9.
28. Muggia F, Kosloff R. Investigational agents for epithelial ovarian cancer. Expert Rev Anticancer Ther 2005;5:855-68.
29. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24:571-8.
30. Alvarez RD, Huh WK, Khazaeli MB, et al. A phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002;8:2806-11.
31. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
32. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006;59:15-26.
33. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
34. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
35. Kaanders J, Pop LAM, Marres HAM, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 1998;48:115-22.
36. Bernier J, Denekamp J, Rojas A, et al. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiother Oncol 2000;55:111-9.
37. van Laarhoven HWM, Bussink J, Lok J, et al. Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen. Radiat Res 2005;164:245-9.
38. van Laarhoven HWM, Bussink J, Lok J, Punt CJA, Heerschap A, van der Kogel AJ. Effects of nicotinamide and carbogen in different murine colon carcinomas: Immunohistochemical analysis of vascular architecture and microenvironmental parameters. Int J Radiat Oncol Biol Phys 2004;60:310-21.
39. Kaanders J, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37.